MetLife director acquires 21 shares via dividend plan

MetLife director Christian Stephane Mumenthaler received additional deferred-plan shares via dividend reinvestment, bringing his direct holdings to 3,474 shares.

Rhea-AI Filing Summary

METLIFE INC (MET) reported that director Christian Stephane Mumenthaler acquired 21 shares of common stock on September 8, 2026 through a grant classified as an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, he holds 3,474 shares directly. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 21 shares

Grant/Award 1 txn

Insider Mumenthaler Christian Stephane

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	21	$95.50	$2K

Holdings After Transaction: Common Stock — 3,474 shares (Direct)

Footnotes (1)

1. F1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Key Figures

Shares acquired: 21 shares Price per share: $95.50 per share Shares held after transaction: 3,474 shares

3 metrics

Shares acquired 21 shares Grant/award acquisition on September 8, 2026

Price per share $95.50 per share Imputed value for dividend reinvestment on acquired shares

Shares held after transaction 3,474 shares Direct holdings of Christian Stephane Mumenthaler after September 8, 2026 transaction

Key Terms

Deferred Compensation Plan for Non-Management Directors, deferred shares, imputed reinvestment of dividends

3 terms

Deferred Compensation Plan for Non-Management Directors financial

"pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors"

deferred shares financial

"Deferred shares represent shares of MetLife, Inc. common stock"

Deferred shares are a class of stock whose economic benefits or certain shareholder rights are delayed or paid later than ordinary shares—for example, dividends may be paid only after other shareholders receive theirs, or voting or redemption rights may be postponed. For investors, that timing difference matters because deferred shares typically offer lower near-term income and different risk, affecting expected returns, priority in payouts, and the share’s market value; think of them like a delayed paycheck compared with a regular salary.

imputed reinvestment of dividends financial

"Imputed reinvestment of dividends on deferred shares pursuant to the MetLife"

FAQ

What insider transaction did MET (MetLife Inc) report for Christian Stephane Mumenthaler?

MetLife reported that director Christian Stephane Mumenthaler acquired 21 shares of common stock on September 8, 2026 as an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

How many MET shares does Christian Stephane Mumenthaler hold after this Form 4 transaction?

After the reported transaction, Christian Stephane Mumenthaler directly holds 3,474 shares of MetLife common stock, according to the Form 4 filing.

What was the reported price for the MET shares acquired by Christian Stephane Mumenthaler?

The 21 MetLife shares acquired by Christian Stephane Mumenthaler were reported at a price of $95.50 per share, reflecting an imputed reinvestment value for dividends on deferred shares.

Was the latest MET insider share acquisition made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not selected, and there is no footnote indicating that Christian Stephane Mumenthaler’s September 8, 2026 share acquisition was made under a Rule 10b5-1 trading plan.

What plan governed the MET deferred-share dividend reinvestment for Christian Stephane Mumenthaler?

The imputed reinvestment of dividends for Christian Stephane Mumenthaler’s 21 acquired shares occurred under the MetLife Deferred Compensation Plan for Non-Management Directors, which involves deferred shares of MetLife common stock that have become payable but whose receipt the director has deferred.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 04:03 PM Accepted by SEC EDGAR 09/10/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mumenthaler Christian Stephane

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NEW YORK 10166

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		A(1)		21	A	$95.5	3,474	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Remarks:

	/s/ Morgan Keehner-Jones Mayes, Attorney-in-fact	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)